Investigational drug · Phase 2
PRO-203
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "PRO-203"
First trial start
2025
Oct 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PRO-203", any sponsor or status.
Conditions studied
As listed on its trial records.
- Healthy Volunteers
- Systemic Sclerosis (SSc)
- Scleroderma, Systemic
- Scleroderma
Largest trials
Live from ClinicalTrials.gov: studies naming "PRO-203" as an intervention, largest first.
- A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.Recruiting
Prolium Bioscience, IncIndustry
NCT07641634 · 44 participants (planned) · Start Oct 27, 2025 · Primary completion Jan 2027
Drug: PRO-203 · For: Healthy Volunteers; Systemic Sclerosis (SSc); Scleroderma, Systemic and 1 more
Sites: Melbourne, Australia; Beijing, China; Guangzhou, China · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Structural features of a bacterial cyclic α-maltosyl-(16)-maltose (CMM) hydrolase critical for CMM recognition and hydrolysis.
Kohno M, Arakawa T, Ota H, et al. · J Biol Chem 2018
- Perturbation of Critical Prolines in Gloeobacter violaceus Ligand-gated Ion Channel (GLIC) Supports Conserved Gating Motions among Cys-loop Receptors.
Rienzo M, Rocchi AR, Threatt SD, et al. · J Biol Chem 2016
- Structure-function studies of the brain-type glucose transporter, GLUT3: alanine-scanning mutagenesis of putative transmembrane helix VIII and an investigation of the role of proline residues in transport catalysis.
Seatter MJ, Kane S, Porter LM, et al. · Biochemistry 1997
Also in development for Healthy Volunteers
- PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease
- PCV21 vaccinePhase 35 trials
Sanofi · Pneumococcal Immunization, Healthy Volunteers
- TDVTAK-003, Tetravalent Dengue VaccinePhase 35 trials
Takeda · Dengue Fever, Healthy Volunteers
- DTap-HepB-IPV-Hib vaccineHexyon, Infanrix hexaPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization
- MenACYW conjugate vaccineNimenrixPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunisation, Meningococcal Immunization
- poliomyelitis vaccinePhase 33 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Whooping Cough, Diphtheria
- HexaximHexaxim Vaccine, DTaP-IPV-Hib-HepB vaccinePhase 32 trials
Sanofi · Pneumococcal Immunization, Meningococcal Immunisation, Healthy Volunteers
- IIV-HDstandalonePhase 32 trials
Sanofi · COVID-19 Immunization, Influenza Immunization, Immunization
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.